BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

WORKING GROUP FOR PHARMACEUTICAL SAFETY — Receipts Report

LD-2 disclosure · 1st Quarter - Amendment

WORKING GROUP FOR PHARMACEUTICAL SAFETY

via BGR GOVERNMENT AFFAIRS

1st Quarter (Jan 1 - Mar 31) · 2015Posted Jul 21, 2015Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: WORKING GROUP FOR PHARMACEUTICAL SAFETY
Description: Advocacy Coalition working to improve pharmaceutical safety
Location: District of Columbia · United States of America

Registrant

Firm: BGR GOVERNMENT AFFAIRS
Description: Lobbying firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Provide guidance and strategic counsel on potential federal legislation and regulations affecting pharmacy compounding.
LobbyistsROBERT WOOD · RYAN LONG
Covered position (ROBERT WOOD): See prior filing
Covered position (RYAN LONG): See prior filing
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.